ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 132 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,709,213 | -29.1% | 85,205 | -0.2% | 0.00% | -50.0% |
| Q2 2023 | $2,409,332 | -25.8% | 85,407 | -54.7% | 0.00% | 0.0% |
| Q1 2023 | $3,245,968 | +58.1% | 188,719 | +85.1% | 0.00% | 0.0% |
| Q4 2022 | $2,052,951 | -43.8% | 101,934 | -39.6% | 0.00% | -33.3% |
| Q3 2022 | $3,656,000 | -0.6% | 168,815 | +29.0% | 0.00% | 0.0% |
| Q2 2022 | $3,677,000 | +153.4% | 130,850 | +316.1% | 0.00% | +200.0% |
| Q1 2022 | $1,451,000 | -72.0% | 31,444 | -49.0% | 0.00% | -66.7% |
| Q4 2021 | $5,184,000 | +129.9% | 61,664 | +82.3% | 0.00% | +200.0% |
| Q3 2021 | $2,255,000 | -44.6% | 33,834 | -55.8% | 0.00% | -50.0% |
| Q2 2021 | $4,074,000 | +14.0% | 76,565 | -7.0% | 0.00% | 0.0% |
| Q1 2021 | $3,574,000 | +471.8% | 82,372 | +585.3% | 0.00% | – |
| Q4 2020 | $625,000 | +3372.2% | 12,020 | +2027.4% | 0.00% | – |
| Q3 2020 | $18,000 | -73.5% | 565 | -59.8% | 0.00% | – |
| Q2 2020 | $68,000 | – | 1,406 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |